Endocannabinoids drive the acquisition of an alternative phenotype in microglia

Brain, Behavior, and Immunity

Volumn 49, Issue , 2015, Pages 233-245

  Mecha, M ^a   Feliu A ^a   Carrillo Salinas, F J ^a   Rueda Zubiaurre, A ^b   Ortega Gutierrez S ^b   de Sola, R García ^c   Guaza, C ^a  

^a INSTITUTO CAJAL   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

2 AG; AEA; CB2 receptors; M2 polarization; Microglia

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; ARGINASE 1; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; FATTY ACID AMIDASE; LIPOPROTEIN LIPASE; SOMATOMEDIN C; SUPPRESSOR OF CYTOKINE SIGNALING 3; 2-ARACHIDONYLGLYCEROL; ACYLGLYCEROL; AMIDE; ARACHIDONIC ACID DERIVATIVE;

ADULT; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; KNOCKOUT MOUSE; MICROGLIA; MICROGLIAL CELL CULTURE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL CULTURE; CELL POLARITY; GENETICS; METABOLISM; PHENOTYPE; PHYSIOLOGY; WISTAR RAT;

ANIMALS; ARACHIDONIC ACIDS; CELL POLARITY; CELLS, CULTURED; ENDOCANNABINOIDS; GLYCERIDES; LIPOPROTEIN LIPASE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROGLIA; PHENOTYPE; POLYUNSATURATED ALKAMIDES; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 84940580235     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2015.06.002     Document Type: Article

References (63)

1. Arévalo-Martín A., García-Ovejero D., Gómez O., Rubio-Araiz A., Navarro-Galve B., Guaza C., Molina-Holgado E., Molina-Holgado F. CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies. Br. J. Pharmacol. 2008, 153(2):216-225.
2. Bisogno T., Howell F., Williams G., Minassi A., Cascio M.G., Ligresti A., Matias I., Schiano-Moriello A., Paul P., Williams E.J., Gangadharan U., Hobbs C., Di Marzo V., Doherty P. Cloning the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell Biol. 2003, 163:436-438.
3. Bisogno T., Di Marzo V. Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. CNS Neurol. Disord. 2010, 9:564-573.
4. Cabral G.A., Griffin-Thomas L. Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev. Mol. Med. 2009, 11:e3.
5. Carlisle S.J., Marciano-Cabral F., Staab A., Ludwick C., Cabral G.A. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int. Immunopharmacol. 2002, 2(1):69-82.
6. Carrier E.J., Kearn C.S., Barkmeier A.J., Breese N.M., Yang W., Nithipatikom K., Pfister S.L., Campbell W.B., Hillard C.J. Cultured rat microglia synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol. Pharmacol. 2004, 65:999-1007.
7. Carrillo-Salinas F.J., Navarrete C., Mecha M., Feliú A., Collado J.A., Cantarero I., Bellido M.L., Muñoz E., Guaza C. A cannabigerol derivative suppresses immune responses and protects mice from experimental autoimmune encephalomyelitis. PLoS One 2014, 20(29):4707-4722.
8. Centonze D., Finazzi-Agrò A., Bernardi G., Maccarrone M. The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol. Sci. 2007, 28(4):180-187.
9. Chhor V., Le Charpentier T., Lebon S., Oré M.V., Celador I.L., Josserand J., Degos V., Jacotot E., Hagberg H., Sävman K., Mallard C., Gressens P., Fleiss B. Characterization of phenotype markers and neuronotoxic potential of polarized primary microglia in vitro. Brain Behav. Immun. 2013, 32:70-85.
10. Chiurchiù V., Lanuti M., Catanzaro G., Fezza F., Rapino C., Maccarrone M. Detailed characterization of the endocannabinoid system in human macrophages and foam cells, and anti-inflammatory role of type-2 cannabinoid receptor. Atherosclerosis 2014, 233:55-63.
11. Colton C.A. Heterogeneity of microglial activation in the innate immune response in the brain. J. Neuroimmune Pharmacol. 2009, 4:399-418.
12. Cravatt B.F., Lichtman A.H. Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr. Opin. Chem. Biol. 2003, 7(4):469-475.
13. Correa F., Docagne F., Mestre L., Clemente D., Hernangómez M., Loría F., Guaza C. A role for CB2 receptors in anandamide signalling pathways involved in the regulation of IL-12 and IL-23 in microglia. Biochem. Pharmacol. 2009, 77(1):86-100.
14. Di Marzo V. Endocannabinoid signaling in the brain: biosynthetic mechanisms in the timelight. Nat. Neurosci. 2011, 14:9-15.
15. Di Marzo V., Bisogno T., De Petrocellis L., Melck D., Orlando P., Wagner J.A., Kunos G. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur. J. Biochem. 1999, 264(1):258-267.
16. Dirikoc S., Priola S.A., Marella M., Zsurger N., Chabry J. Nonpsychoactive cannabidiol prevents prion accumulation and protects neurons against prion toxicity. J. Neurosci. 2007, 27:9537-9544.
17. Durafourt B.A., Moore C.S., Blain M., Antel J. Isolating, culturing and polarizing primary human adult and fetal microglia. Microglia Methods and Protocols 2013, 199-211. Humana Press, Springer, New York. Joseph-Venero (Ed.).
18. Ehrhart J., Obregon D., Mori T., Hou H., Sun N., Bai Y., Klein T., Fernandez F., Tan J., Shytle R.D. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J. Neuroinflam. 2005, 2:29.
19. Eljaschewitsch E., Witting A., Mawrin C., Lee T., Schmidt P.M., Wolf S., Hoertnagl H., Raine C.S., Schneider-Stock R., Nitsch R., Ullrich O. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 2006, 49:67-79.
20. Feliú, A., Moreno-Martet, M., Mecha, M., Carrillo-Salinas, F.J., de Lago, E., Fernández-Ruiz, J., Guaza, C. A sativex-like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis. Br. J. Pharmacol. 2015 (Epub ahead of print).
21. Fowler C.J. Anandamide uptake explained?. Trends Pharmacol. Sci. 2012, 33:181-185.
22. Freund T.F., Katona I., Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 2003, 83:1017-1066.
23. García-Ovejero D., Arévalo-Martín Á., Navarro-Galve B., Pinteaux E., Molina-Holgado E., Molina-Holgado F. Neuroimmmune interactions of cannabinoids in neurogenesis: focus on interleukin-1β (IL-1β) signaling. Biochem. Soc. Trans. 2013, 41(6):1577-1582.
24. Gokoh M., Kishimoto S., Oka S., Sugiura T. 2-Arachidonoylglycerol enhances the phagocytosis of opsonized zymosan by HL-60 cells differentiated into macrophage-like cells. Biol. Pharm. Bull. 2007, 30:1199-1205.
25. Gómez O., Arévalo-Martín A., García-Ovejero D., Ortega-Gutiérrez S., Cisneros J.A., Almazán G., Sánchez-Rodriguez M.A., Molina-Holgado F., Molina-Holgado E. The constitutive production of the endocannabinoide 2-arachidonoylglycerol participates in oligodendrocyte differentiation. Glia 2010, 58(16):1913-1927.
26. Gonsiorek W., Lunn C., Fan X., Narula S., Lundell D., Hipkin R.W. Endocannabinoid 2-arachidonylglycerol is a full agonist through human type 2 cannabinod receptor: antagonism by anandamide. Mol. Pharmacol. 2000, 57(5):1045-1050.
27. Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol. 2003, 3(1):23-35.
28. Griffin G., Tao Q., Abood M.E. Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor. J. Pharmacol. Exp. Ther. 2000, 292:886-894.
29. Hernangómez M., Carrillo-Salinas F.J., Mecha M., Correa F., Mestre L., Loría F., Feliú A., Docagne F., Guaza C. Brain innate immunity in the regulation of neuroinflammation: therapeutic strategies by modulating CD200-CD200R interaction involve the cannabinoid system. Curr. Pharm. Des. 2014, 20(29):4707-4722.
30. Hernández-Torres G., Cipriano M., Hedén E., Björklund E., Canales A., Zian D., Feliú A., Mecha M., Guaza C., Fowler C.J., Ortega-Gutiérrez S., López-Rodríguez M.L. A reversible and selective inhibitor of monoacylglycerol lipase ameliorates multiple sclerosis. Angew. Chem. Int. Ed. 2014, 53(50):13765-13770.
31. Hillard C.J. Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostaglandins Other Lipids Mediat. 2000, 61(1-2):3-18.
32. Hu X., Leak R.K., Shi Y., Suenaga J., Gao Y., Zheng P., Chen J. Microglial and macrophage polarization-new prospects for brain repair. Nat. Rev. Neurol. 2015, 11(1):56-64.
33. Litchman A.H., Blankman J.L., Cravatt B.J. Endocannabinoid overload. Mol. Pharmacol. 2010, 78:993-995.
34. Liu J., Batkai S., Pacher P., Harvey-White J., Wagner J.A., Cravatt B.F., Gao B., Kunos G. Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-kappaB independently of platelet-activated factor. J. Biol. Chem. 2003, 278(45):45034-45039.
35. Liu J., Wang L., Harvey-White J., Osei-Hyiaman D., Razdan R.K., Zhou Z., Chen A., Huang B., Kim H.Y., Kunos G. Novel biosynthetic pathway for anandamide. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:13345-13350.
36. MacMicking J., Xie Q.W., Nathan C. Nitric oxide and macrophage function. Annu. Rev. Immunol. 1997, 15:323-350.
37. McCarthy K.D., De Vellis J. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J. Cell Biol. 1980, 85:890-902.
38. Maresz K., Carrier E.J., Ponomarev E.D., Hillard C.J., Dittel B.N. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J. Neurochem. 2005, 95(2):437-445.
39. Maroof N., Pardon M.C., Kendall D.A. Endocannabinoid signalling in Alzheimer's disease. Biochem. Soc. Trans. 2013, 41(6):1583-1587.
40. Martín-Couce L., Martín-Fontecha M., Palomares O., Mestre L., Cordomí A., Hernángomez M., Palma S., Pardo L., Guaza C., López-Rodríguez M.L., Ortega-Gutiérrez S. Chemical probes for the recognition of cannabinoid receptors in native systems. Angew. Chem. Int. Ed. 2012, 51(28):6896-6899.
41. Mechoulam R., Parker L.A. The endocannabinoid system and the brain. Ann. Rev. Psychol. 2013, 64:21-47.
42. Medina-Rodríguez E.M., Arenzana F.J., Bribián A., de Castro F. Protocol to isolate a large amount of functional oligodendrocyte precursor cells from the cerebral cortex of adult mice and humans. PLoS One 2013, 8(11):e81620.
43. Melief J., Koning N., Schuurman K.G., Van de Garde M.D., Smolders J., Hoek R.M., Van Eijk M., Hamman J., Huitinga I. Phenotyping primary human microglia: tight regulation of LPS responsiveness. Glia 2012, 60(10):1506-1517.
44. Miller L.K., Devi L.A. The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. Pharmacol. Rev. 2011, 63(3):461-470.
45. Murataeva N., Straiker A., Mackie K. Parsing the players: 2-arachidonoylglycerol synthesis and degradation in the CNS. Br. J. Pharmacol. 2014, 171:1379-1391.
46. Neumann H., Kotter M.R., Franklin R.J.M. Debris clearance by microglia: an essential link between degeneration and regeneration. Brain 2009, 132:288-295.
47. Novak M.L., Koh T.J. Macrophage phenotypes during tissue repair. J. Leukoc. Biol. 2013, 93(6):875-881.
48. Ortega-Gutiérrez S., Molina-Holgado E., Arévalo-Martín A., Correa F., Viso A., López-Rodríguez M.L., Di Marzo V., Guaza C. Activation of the endocannabinoid system as a therapeutic approach in a murine model of multiple sclerosis. FASEB J. 2005, 19:1338-1340.
49. Pacher P., Bátkai S., Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 2008, 58(3):389-462.
50. Pertwee R.G. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr. Med. Chem. 2010, 17(14):1360-1381.
51. Raes G., Brys L., Dahal B.K., Brandt J., Grooten J., Brombacher F., Vanham G., Noël W., Boqaert P., Boonefaes T., Kindt A., Van den Bergh R., Leenen P.J., De Baetselier P., Ghassabeh G.H. Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation. J. Leukoc. Biol. 2005, 77(3):321-327.
52. Ramírez B.G., Blázquez C., Gómez del Pulgar T., Guzmán M., de Ceballos M.L. Prevention of Alzheimeŕs disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 2005, 25:1904-1913.
53. Salzet M., Breton C., Bisogno T., Di Marzo V. Comparative biology of the endocannabinoid system: possible role in the immune response. Eur. J. Biochem. 2000, 267(16):4917-4927.
54. Shiratsuchi A., Watanabe I., Yoshida H., Nakanishi Y. Involvement of cannabinoid receptor CB2 in dectin-1-mediated macrophage phagocytosis. Immunol. Cell Biol. 2008, 86:179-184.
55. Simon G.M., Cravatt B.F. Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta hydrolase 4 in this pathway. J. Biol. Chem. 2006, 281(36):26465-26472.
56. Spittau B., Wullkopf L., Zhou X., Rilka J., Pfeifer D., Krieglstein K. Endogenous transforming growth factor-beta promotes quiescence of primary microglia in vitro. Glia 2013, 61(2):287-300.
57. Spittau B., Rilka J., Steinfath E., Zöller T., Krieglstein K. TGFß1 increases microglia-mediated engulfment of apoptotic cells via upregulation of the milk fat globule-EGF factor 8. Glia 2015, 63(1):142-153.
58. Stein M., Keshav S., Harris N., Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J. Exp. Med. 1992, 176:287-292.
59. Stella N., Schweitzer P., Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997, 338(6644):773-778.
60. Stella N. Endocannabiniod signaling in microglial cells. Neuropharmacology 2009, 56:244-253.
61. Tolón R.M., Núñez E., Pazos M.R., Benito C., Castillo A.I., Martínez-Orgado J.A., Romero J. The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages. Brain Res. 2009, 1283:148-154.
62. Walter L., Franklin A., Witting A., Wade C., Xie Y., Kunos G., Mackie K., Stella N. Non-psychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci. 2003, 23:1398-1405.
63. Zhang J., Hoffert C., Vu H.K., Groblewski T., Ahmad S., ÓDonnell D. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur. J. Neurosci. 2003, 17(12):2750-2754.